咸蛋超人POT personal page - To The Moon

咸蛋超人POT

咸蛋超人POT

Profile：股票呆呆

10Follow

4Followers

0Topic

0Badge

咸蛋超人POT

2022-12-15

BBQ ler

1 Nasdaq Stock to Avoid Like the Plague in 2023, and 1 to Buy Hand Over Fist

咸蛋超人POT

2021-12-23

The drug ha side effects

Biogen shares fell 1.2% in early trading

咸蛋超人POT

2021-12-18

Time to trap the short sellers

Sorry, the original content has been removed

咸蛋超人POT

2021-09-03

$Cassava Sciences Inc(SAVA)$It's almost time to average in at current price levels. Baby steps at a time, go easy. [YoYo] [Call]

咸蛋超人POT

2021-08-28

$Cassava Sciences Inc(SAVA)$Lunch break isover, time to go GREEN![Smart]

咸蛋超人POT

2021-08-28

$Cassava Sciences Inc(SAVA)$ SQUEEZE the BEARS!!!

咸蛋超人POT

2021-08-27

$Cassava Sciences Inc(SAVA)$ Cassava Sciences Releases Statement Regarding Plasma p-tau (globenewswire.com)

咸蛋超人POT

2021-04-29

$Castor Maritime, Inc.(CTRM)$ have put this ticker in storage; will look back on it months later :O

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3575010783330312,"uuid":"3575010783330312","gmtCreate":1612181250199,"gmtModify":1636088794261,"name":"咸蛋超人POT","pinyin":"xdcrpotxiandanchaorenpot","introduction":"","introductionEn":null,"signature":"股票呆呆","avatar":"https://static.tigerbbs.com/ffe12d12ec49236cc05d807be8348dc0","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":10,"tweetSize":24,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.84%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.56%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9921593734,"gmtCreate":1671080909728,"gmtModify":1676538487015,"author":{"id":"3575010783330312","authorId":"3575010783330312","name":"咸蛋超人POT","avatar":"https://static.tigerbbs.com/ffe12d12ec49236cc05d807be8348dc0","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"BBQ ler","listText":"BBQ ler","text":"BBQ ler","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921593734","repostId":"2291796194","repostType":2,"repost":{"id":"2291796194","pubTimestamp":1671076649,"share":"https://www.laohu8.com/m/news/2291796194?lang=&edition=full","pubTime":"2022-12-15 11:57","market":"us","language":"en","title":"1 Nasdaq Stock to Avoid Like the Plague in 2023, and 1 to Buy Hand Over Fist","url":"https://stock-news.laohu8.com/highlight/detail?id=2291796194","media":"Motley Fool","summary":"A bull market in 2023 could give one of these Nasdaq names a nice boost.","content":"<html><head></head><body><p>With 2022 about to come to an end, it is safe to say that this has been a year investors would like to forget. It has been a terrible one for the stock market, as evidenced by the steep 30% decline in the <b>Nasdaq Composite </b>index so far this year.</p><p>The good news for investors is that there&#39;s potential for a bull market next year as slowing inflation could lead the Federal Reserve to ease the pace of interest rate hikes. That makes now a good time to consider a beaten-down Nasdaq stock with the potential to take off in 2023. At the same time, investors should steer clear of certain Nasdaq names that may continue to struggle even in a bull market.</p><p><b>Micron Technology</b> and <b>Microsoft</b> have borne the brunt of the Nasdaq&#39;s drop this year. Micron is down 41% in 2022 and shares of Microsoft have dropped 27%. One of these two Nasdaq stocks is likely to take off in the new year and the other one could continue to struggle.</p><p>Let&#39;s see which one of these tech stocks investors should consider buying hand over fist and which one they should be avoiding like the plague.</p><h2>Micron Technology is going to enter the new year on the back foot</h2><p>The decline in the demand for memory chips this year really hit Micron stock. <b>Gartner</b> estimates that sales of dynamic random access memory (DRAM) chips that are used in personal computers (PCs), smartphones, workstations, and data centers could decline 2.6% in 2022 to $90.5 billion. That&#39;s not surprising as sales of both smartphones and PCs dropped this year.</p><p>DRAM chips produced 72% of Micron&#39;s total revenue in the fourth quarter of fiscal 2022 (for the three months ending Sept. 1). This explains why lower DRAM shipments combined with a drop in average selling prices led to a 20% year-over-year decline in the chipmaker&#39;s quarterly revenue to $6.6 billion. The memory specialist&#39;s non-GAAP (adjusted) earnings fell to $1.45 per share from $2.42 per share in the prior-year period as the adjusted operating margin shrank to 25% from 37.1% in the prior year.</p><p>The new year could be even worse for Micron. That&#39;s because Gartner sees DRAM industry revenue declining at a greater pace of 18% in 2023 to $74 billion. Meanwhile, the NAND flash memory business that produced 25% of Micron&#39;s revenue last quarter is also anticipated to turn negative next year. Gartner estimates a 13.7% decline in NAND flash industry revenue to $59 billion following a 4.4% increment in 2022.</p><p>Not surprisingly, Micron&#39;s guidance for the first quarter of fiscal 2023 suggests it is about to have a terrible year. The chipmaker guided for $4.25 billion in revenue and $0.07 per share in earnings, which would translate into a huge decline over the prior-year period&#39;s revenue of $7.69 billion and adjusted earnings of $2.16 per share.</p><p>Even worse, analysts forecast a 40% drop in Micron&#39;s top line in fiscal 2023. Its earnings are expected to shrink to just $0.25 per share from fiscal 2022&#39;s figure of $8.35 per share. These numbers suggest that Micron could head lower in the new year, which is why investors should steer clear of this struggling tech stock.</p><h2>Microsoft could step on the gas</h2><p>Microsoft&#39;s woeful stock market performance in 2022 means that investors can buy this technology giant on the cheap right now. Microsoft stock is trading at 26 times earnings, a discount to its five-year average multiple of 37. Investors may not want to let such an opportunity slip by considering that Microsoft&#39;s growth is expected to pick up the pace.</p><p>In the first quarter of fiscal 2023, which ended on Sept. 30, Microsoft clocked $50.1 billion in revenue, an increase of 11% over the year-ago period. The tech giant&#39;s revenue was up 16% year over year in constant currency terms. Analysts expect Microsoft to finish the fiscal year with 7% revenue growth, but fiscal 2024 is expected to be stronger with a 13% spike in revenue to $241 billion.</p><p>What&#39;s more, the company&#39;s momentum is anticipated to continue in fiscal 2025 as well.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c0a2ff6cb18a6fae2897305b7fc6ccd4\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>MSFT Revenue Estimates for Current Fiscal Year data by YCharts</span></p><p>It is impressive to see Microsoft thriving at a time when sales of personal computers are declining and the video gaming market is not in the best of health. Microsoft&#39;s reliance on cloud computing for a huge chunk of its revenue helped it offset the weakness in other markets.</p><p>More specifically, Microsoft&#39;s revenue from the intelligent cloud segment increased an impressive 20% year over year last quarter to $20.3 billion, accounting for 40% of the company&#39;s top line. Synergy Research Group estimates that Microsoft controlled 21% of the cloud infrastructure market in the third quarter of 2022. The market research firm also added that the cloud infrastructure service market in which Microsoft operates generated $217 billion in revenue in the trailing 12 months that ended in September.</p><p>Mordor Intelligence forecasts that the cloud infrastructure services market could clock annual growth of 19% through 2026, suggesting that Microsoft&#39;s biggest business is on track to become bigger in the long run. Meanwhile, a recovery in the video gaming market should help Microsoft&#39;s Xbox business turn around in the long run.</p><p>Microsoft&#39;s revenue from the Xbox content and services business was down 3% year over year last quarter. Newzoo predicts that the global gaming market is on track to contract 4% this year to $184.4 billion, which explains the weakness in Microsoft&#39;s gaming business. But by 2025, the global games market is expected to generate $211.2 billion in revenue.</p><p>This secular growth opportunity combined with Microsoft&#39;s steps to corner a bigger share of the video gaming market should give investors optimism about the health of the gaming business in the long run.</p><p>In all, Microsoft could see better days in 2023 and beyond thanks to the catalysts discussed above, which is why savvy investors should consider buying it given the attractive valuation.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Nasdaq Stock to Avoid Like the Plague in 2023, and 1 to Buy Hand Over Fist</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Nasdaq Stock to Avoid Like the Plague in 2023, and 1 to Buy Hand Over Fist\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-15 11:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/13/1-nasdaq-stock-to-avoid-2023-and-1-to-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>With 2022 about to come to an end, it is safe to say that this has been a year investors would like to forget. It has been a terrible one for the stock market, as evidenced by the steep 30% decline in...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/13/1-nasdaq-stock-to-avoid-2023-and-1-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4581":"高盛持仓","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","BK4512":"苹果概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0061474705.USD":"THREADNEEDLE (LUX) GLOBAL DYNAMIC REAL RETURN \"AU\" (USD) ACC","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","BK4548":"巴美列捷福持仓","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0276348264.USD":"THREADNEEDLE (LUX) GLOBAL DYNAMIC REAL RETURN\"AUP\" (USD) INC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","IE00BFSS8Q28.SGD":"Janus Henderson Balanced A Inc SGD-H","BK4528":"SaaS概念","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","BK4554":"元宇宙及AR概念","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","LU2286300806.USD":"Allianz Cyber Security AT Acc USD","BK4532":"文艺复兴科技持仓","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","BK4553":"喜马拉雅资本持仓","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","BK4567":"ESG概念","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4534":"瑞士信贷持仓","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","BK4576":"AR","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","MU":"美光科技","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","BK4575":"芯片概念","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","MSFT":"微软","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC","BK4535":"淡马锡持仓","LU0079474960.USD":"联博美国增长基金A","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","BK4141":"半导体产品","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","LU0061474960.USD":"天利环球焦点基金AU Acc","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0308772762.SGD":"Blackrock Global Allocation A2 SGD-H","BK4503":"景林资产持仓","LU0109392836.USD":"富兰克林科技股A","BK4097":"系统软件"},"source_url":"https://www.fool.com/investing/2022/12/13/1-nasdaq-stock-to-avoid-2023-and-1-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2291796194","content_text":"With 2022 about to come to an end, it is safe to say that this has been a year investors would like to forget. It has been a terrible one for the stock market, as evidenced by the steep 30% decline in the Nasdaq Composite index so far this year.The good news for investors is that there's potential for a bull market next year as slowing inflation could lead the Federal Reserve to ease the pace of interest rate hikes. That makes now a good time to consider a beaten-down Nasdaq stock with the potential to take off in 2023. At the same time, investors should steer clear of certain Nasdaq names that may continue to struggle even in a bull market.Micron Technology and Microsoft have borne the brunt of the Nasdaq's drop this year. Micron is down 41% in 2022 and shares of Microsoft have dropped 27%. One of these two Nasdaq stocks is likely to take off in the new year and the other one could continue to struggle.Let's see which one of these tech stocks investors should consider buying hand over fist and which one they should be avoiding like the plague.Micron Technology is going to enter the new year on the back footThe decline in the demand for memory chips this year really hit Micron stock. Gartner estimates that sales of dynamic random access memory (DRAM) chips that are used in personal computers (PCs), smartphones, workstations, and data centers could decline 2.6% in 2022 to $90.5 billion. That's not surprising as sales of both smartphones and PCs dropped this year.DRAM chips produced 72% of Micron's total revenue in the fourth quarter of fiscal 2022 (for the three months ending Sept. 1). This explains why lower DRAM shipments combined with a drop in average selling prices led to a 20% year-over-year decline in the chipmaker's quarterly revenue to $6.6 billion. The memory specialist's non-GAAP (adjusted) earnings fell to $1.45 per share from $2.42 per share in the prior-year period as the adjusted operating margin shrank to 25% from 37.1% in the prior year.The new year could be even worse for Micron. That's because Gartner sees DRAM industry revenue declining at a greater pace of 18% in 2023 to $74 billion. Meanwhile, the NAND flash memory business that produced 25% of Micron's revenue last quarter is also anticipated to turn negative next year. Gartner estimates a 13.7% decline in NAND flash industry revenue to $59 billion following a 4.4% increment in 2022.Not surprisingly, Micron's guidance for the first quarter of fiscal 2023 suggests it is about to have a terrible year. The chipmaker guided for $4.25 billion in revenue and $0.07 per share in earnings, which would translate into a huge decline over the prior-year period's revenue of $7.69 billion and adjusted earnings of $2.16 per share.Even worse, analysts forecast a 40% drop in Micron's top line in fiscal 2023. Its earnings are expected to shrink to just $0.25 per share from fiscal 2022's figure of $8.35 per share. These numbers suggest that Micron could head lower in the new year, which is why investors should steer clear of this struggling tech stock.Microsoft could step on the gasMicrosoft's woeful stock market performance in 2022 means that investors can buy this technology giant on the cheap right now. Microsoft stock is trading at 26 times earnings, a discount to its five-year average multiple of 37. Investors may not want to let such an opportunity slip by considering that Microsoft's growth is expected to pick up the pace.In the first quarter of fiscal 2023, which ended on Sept. 30, Microsoft clocked $50.1 billion in revenue, an increase of 11% over the year-ago period. The tech giant's revenue was up 16% year over year in constant currency terms. Analysts expect Microsoft to finish the fiscal year with 7% revenue growth, but fiscal 2024 is expected to be stronger with a 13% spike in revenue to $241 billion.What's more, the company's momentum is anticipated to continue in fiscal 2025 as well.MSFT Revenue Estimates for Current Fiscal Year data by YChartsIt is impressive to see Microsoft thriving at a time when sales of personal computers are declining and the video gaming market is not in the best of health. Microsoft's reliance on cloud computing for a huge chunk of its revenue helped it offset the weakness in other markets.More specifically, Microsoft's revenue from the intelligent cloud segment increased an impressive 20% year over year last quarter to $20.3 billion, accounting for 40% of the company's top line. Synergy Research Group estimates that Microsoft controlled 21% of the cloud infrastructure market in the third quarter of 2022. The market research firm also added that the cloud infrastructure service market in which Microsoft operates generated $217 billion in revenue in the trailing 12 months that ended in September.Mordor Intelligence forecasts that the cloud infrastructure services market could clock annual growth of 19% through 2026, suggesting that Microsoft's biggest business is on track to become bigger in the long run. Meanwhile, a recovery in the video gaming market should help Microsoft's Xbox business turn around in the long run.Microsoft's revenue from the Xbox content and services business was down 3% year over year last quarter. Newzoo predicts that the global gaming market is on track to contract 4% this year to $184.4 billion, which explains the weakness in Microsoft's gaming business. But by 2025, the global games market is expected to generate $211.2 billion in revenue.This secular growth opportunity combined with Microsoft's steps to corner a bigger share of the video gaming market should give investors optimism about the health of the gaming business in the long run.In all, Microsoft could see better days in 2023 and beyond thanks to the catalysts discussed above, which is why savvy investors should consider buying it given the attractive valuation.","news_type":1},"isVote":1,"tweetType":1,"viewCount":181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9000230410,"gmtCreate":1640191181689,"gmtModify":1676533506185,"author":{"id":"3575010783330312","authorId":"3575010783330312","name":"咸蛋超人POT","avatar":"https://static.tigerbbs.com/ffe12d12ec49236cc05d807be8348dc0","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"The drug ha side effects","listText":"The drug ha side effects","text":"The drug ha side effects","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000230410","repostId":"1104039472","repostType":4,"repost":{"id":"1104039472","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640184691,"share":"https://www.laohu8.com/m/news/1104039472?lang=&edition=full","pubTime":"2021-12-22 22:51","market":"us","language":"en","title":"Biogen shares fell 1.2% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1104039472","media":"Tiger Newspress","summary":"Biogen shares fell 1.2% in early trading.A Japanese health ministry panel said on Wednesday that inc","content":"<p>Biogen&nbsp;shares&nbsp;fell&nbsp;1.2%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/22ab29bf4110d582a44955c778f3cf48\" tg-width=\"713\" tg-height=\"596\" width=\"100%\" height=\"auto\">A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.</p>\n<p>Tokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.</p>\n<p>In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen shares fell 1.2% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen shares fell 1.2% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-22 22:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biogen&nbsp;shares&nbsp;fell&nbsp;1.2%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/22ab29bf4110d582a44955c778f3cf48\" tg-width=\"713\" tg-height=\"596\" width=\"100%\" height=\"auto\">A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.</p>\n<p>Tokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.</p>\n<p>In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104039472","content_text":"Biogen shares fell 1.2% in early trading.A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.\nTokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.\nIn a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.","news_type":1},"isVote":1,"tweetType":1,"viewCount":343,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9000976274,"gmtCreate":1639789385814,"gmtModify":1676533494531,"author":{"id":"3575010783330312","authorId":"3575010783330312","name":"咸蛋超人POT","avatar":"https://static.tigerbbs.com/ffe12d12ec49236cc05d807be8348dc0","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Time to trap the short sellers","listText":"Time to trap the short sellers","text":"Time to trap the short sellers","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000976274","repostId":"1108682296","repostType":2,"isVote":1,"tweetType":1,"viewCount":223,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815834802,"gmtCreate":1630664153206,"gmtModify":1676530369992,"author":{"id":"3575010783330312","authorId":"3575010783330312","name":"咸蛋超人POT","avatar":"https://static.tigerbbs.com/ffe12d12ec49236cc05d807be8348dc0","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>It's almost time to average in at current price levels. &nbsp;Baby steps at a time, go easy. &nbsp;[YoYo]&nbsp;[Call]&nbsp;","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>It's almost time to average in at current price levels. &nbsp;Baby steps at a time, go easy. &nbsp;[YoYo]&nbsp;[Call]&nbsp;","text":"$Cassava Sciences Inc(SAVA)$It's almost time to average in at current price levels. Baby steps at a time, go easy. [YoYo] [Call]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815834802","isVote":1,"tweetType":1,"viewCount":272,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819437902,"gmtCreate":1630085057706,"gmtModify":1676530221747,"author":{"id":"3575010783330312","authorId":"3575010783330312","name":"咸蛋超人POT","avatar":"https://static.tigerbbs.com/ffe12d12ec49236cc05d807be8348dc0","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Lunch break isover, time to go GREEN![Smart]&nbsp;","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Lunch break isover, time to go GREEN![Smart]&nbsp;","text":"$Cassava Sciences Inc(SAVA)$Lunch break isover, time to go GREEN![Smart]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819437902","isVote":1,"tweetType":1,"viewCount":448,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819544328,"gmtCreate":1630080347364,"gmtModify":1676530220694,"author":{"id":"3575010783330312","authorId":"3575010783330312","name":"咸蛋超人POT","avatar":"https://static.tigerbbs.com/ffe12d12ec49236cc05d807be8348dc0","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a> SQUEEZE the BEARS!!!","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a> SQUEEZE the BEARS!!!","text":"$Cassava Sciences Inc(SAVA)$ SQUEEZE the BEARS!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819544328","isVote":1,"tweetType":1,"viewCount":205,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819524151,"gmtCreate":1630079037573,"gmtModify":1676530220178,"author":{"id":"3575010783330312","authorId":"3575010783330312","name":"咸蛋超人POT","avatar":"https://static.tigerbbs.com/ffe12d12ec49236cc05d807be8348dc0","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a> Cassava Sciences Releases Statement Regarding Plasma p-tau (globenewswire.com)","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a> Cassava Sciences Releases Statement Regarding Plasma p-tau (globenewswire.com)","text":"$Cassava Sciences Inc(SAVA)$ Cassava Sciences Releases Statement Regarding Plasma p-tau (globenewswire.com)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819524151","isVote":1,"tweetType":1,"viewCount":339,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":109878404,"gmtCreate":1619686563408,"gmtModify":1704728003790,"author":{"id":"3575010783330312","authorId":"3575010783330312","name":"咸蛋超人POT","avatar":"https://static.tigerbbs.com/ffe12d12ec49236cc05d807be8348dc0","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a> have put this ticker in storage; will look back on it months later :O","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a> have put this ticker in storage; will look back on it months later :O","text":"$Castor Maritime, Inc.(CTRM)$ have put this ticker in storage; will look back on it months later :O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/109878404","isVote":1,"tweetType":1,"viewCount":1153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":109878404,"gmtCreate":1619686563408,"gmtModify":1704728003790,"author":{"id":"3575010783330312","authorId":"3575010783330312","name":"咸蛋超人POT","avatar":"https://static.tigerbbs.com/ffe12d12ec49236cc05d807be8348dc0","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a> have put this ticker in storage; will look back on it months later :O","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/CTRM\">$Castor Maritime, Inc.(CTRM)$</a> have put this ticker in storage; will look back on it months later :O","text":"$Castor Maritime, Inc.(CTRM)$ have put this ticker in storage; will look back on it months later :O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/109878404","isVote":1,"tweetType":1,"viewCount":1153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819544328,"gmtCreate":1630080347364,"gmtModify":1676530220694,"author":{"id":"3575010783330312","authorId":"3575010783330312","name":"咸蛋超人POT","avatar":"https://static.tigerbbs.com/ffe12d12ec49236cc05d807be8348dc0","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a> SQUEEZE the BEARS!!!","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a> SQUEEZE the BEARS!!!","text":"$Cassava Sciences Inc(SAVA)$ SQUEEZE the BEARS!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819544328","isVote":1,"tweetType":1,"viewCount":205,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9000230410,"gmtCreate":1640191181689,"gmtModify":1676533506185,"author":{"id":"3575010783330312","authorId":"3575010783330312","name":"咸蛋超人POT","avatar":"https://static.tigerbbs.com/ffe12d12ec49236cc05d807be8348dc0","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"The drug ha side effects","listText":"The drug ha side effects","text":"The drug ha side effects","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000230410","repostId":"1104039472","repostType":4,"repost":{"id":"1104039472","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640184691,"share":"https://www.laohu8.com/m/news/1104039472?lang=&edition=full","pubTime":"2021-12-22 22:51","market":"us","language":"en","title":"Biogen shares fell 1.2% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1104039472","media":"Tiger Newspress","summary":"Biogen shares fell 1.2% in early trading.A Japanese health ministry panel said on Wednesday that inc","content":"<p>Biogen&nbsp;shares&nbsp;fell&nbsp;1.2%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/22ab29bf4110d582a44955c778f3cf48\" tg-width=\"713\" tg-height=\"596\" width=\"100%\" height=\"auto\">A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.</p>\n<p>Tokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.</p>\n<p>In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen shares fell 1.2% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen shares fell 1.2% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-22 22:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biogen&nbsp;shares&nbsp;fell&nbsp;1.2%&nbsp;in&nbsp;early&nbsp;trading.<img src=\"https://static.tigerbbs.com/22ab29bf4110d582a44955c778f3cf48\" tg-width=\"713\" tg-height=\"596\" width=\"100%\" height=\"auto\">A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.</p>\n<p>Tokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.</p>\n<p>In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104039472","content_text":"Biogen shares fell 1.2% in early trading.A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co and Biogen Inc.\nTokyo-based Eisai and its United States partner filed for Japanese regulatory approval just over a year ago for the drug Aduhelm, which was approved in the United States in June.\nIn a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. The panel said it would take another look if further data is submitted.","news_type":1},"isVote":1,"tweetType":1,"viewCount":343,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819524151,"gmtCreate":1630079037573,"gmtModify":1676530220178,"author":{"id":"3575010783330312","authorId":"3575010783330312","name":"咸蛋超人POT","avatar":"https://static.tigerbbs.com/ffe12d12ec49236cc05d807be8348dc0","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a> Cassava Sciences Releases Statement Regarding Plasma p-tau (globenewswire.com)","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a> Cassava Sciences Releases Statement Regarding Plasma p-tau (globenewswire.com)","text":"$Cassava Sciences Inc(SAVA)$ Cassava Sciences Releases Statement Regarding Plasma p-tau (globenewswire.com)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819524151","isVote":1,"tweetType":1,"viewCount":339,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9921593734,"gmtCreate":1671080909728,"gmtModify":1676538487015,"author":{"id":"3575010783330312","authorId":"3575010783330312","name":"咸蛋超人POT","avatar":"https://static.tigerbbs.com/ffe12d12ec49236cc05d807be8348dc0","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"BBQ ler","listText":"BBQ ler","text":"BBQ ler","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921593734","repostId":"2291796194","repostType":2,"repost":{"id":"2291796194","pubTimestamp":1671076649,"share":"https://www.laohu8.com/m/news/2291796194?lang=&edition=full","pubTime":"2022-12-15 11:57","market":"us","language":"en","title":"1 Nasdaq Stock to Avoid Like the Plague in 2023, and 1 to Buy Hand Over Fist","url":"https://stock-news.laohu8.com/highlight/detail?id=2291796194","media":"Motley Fool","summary":"A bull market in 2023 could give one of these Nasdaq names a nice boost.","content":"<html><head></head><body><p>With 2022 about to come to an end, it is safe to say that this has been a year investors would like to forget. It has been a terrible one for the stock market, as evidenced by the steep 30% decline in the <b>Nasdaq Composite </b>index so far this year.</p><p>The good news for investors is that there&#39;s potential for a bull market next year as slowing inflation could lead the Federal Reserve to ease the pace of interest rate hikes. That makes now a good time to consider a beaten-down Nasdaq stock with the potential to take off in 2023. At the same time, investors should steer clear of certain Nasdaq names that may continue to struggle even in a bull market.</p><p><b>Micron Technology</b> and <b>Microsoft</b> have borne the brunt of the Nasdaq&#39;s drop this year. Micron is down 41% in 2022 and shares of Microsoft have dropped 27%. One of these two Nasdaq stocks is likely to take off in the new year and the other one could continue to struggle.</p><p>Let&#39;s see which one of these tech stocks investors should consider buying hand over fist and which one they should be avoiding like the plague.</p><h2>Micron Technology is going to enter the new year on the back foot</h2><p>The decline in the demand for memory chips this year really hit Micron stock. <b>Gartner</b> estimates that sales of dynamic random access memory (DRAM) chips that are used in personal computers (PCs), smartphones, workstations, and data centers could decline 2.6% in 2022 to $90.5 billion. That&#39;s not surprising as sales of both smartphones and PCs dropped this year.</p><p>DRAM chips produced 72% of Micron&#39;s total revenue in the fourth quarter of fiscal 2022 (for the three months ending Sept. 1). This explains why lower DRAM shipments combined with a drop in average selling prices led to a 20% year-over-year decline in the chipmaker&#39;s quarterly revenue to $6.6 billion. The memory specialist&#39;s non-GAAP (adjusted) earnings fell to $1.45 per share from $2.42 per share in the prior-year period as the adjusted operating margin shrank to 25% from 37.1% in the prior year.</p><p>The new year could be even worse for Micron. That&#39;s because Gartner sees DRAM industry revenue declining at a greater pace of 18% in 2023 to $74 billion. Meanwhile, the NAND flash memory business that produced 25% of Micron&#39;s revenue last quarter is also anticipated to turn negative next year. Gartner estimates a 13.7% decline in NAND flash industry revenue to $59 billion following a 4.4% increment in 2022.</p><p>Not surprisingly, Micron&#39;s guidance for the first quarter of fiscal 2023 suggests it is about to have a terrible year. The chipmaker guided for $4.25 billion in revenue and $0.07 per share in earnings, which would translate into a huge decline over the prior-year period&#39;s revenue of $7.69 billion and adjusted earnings of $2.16 per share.</p><p>Even worse, analysts forecast a 40% drop in Micron&#39;s top line in fiscal 2023. Its earnings are expected to shrink to just $0.25 per share from fiscal 2022&#39;s figure of $8.35 per share. These numbers suggest that Micron could head lower in the new year, which is why investors should steer clear of this struggling tech stock.</p><h2>Microsoft could step on the gas</h2><p>Microsoft&#39;s woeful stock market performance in 2022 means that investors can buy this technology giant on the cheap right now. Microsoft stock is trading at 26 times earnings, a discount to its five-year average multiple of 37. Investors may not want to let such an opportunity slip by considering that Microsoft&#39;s growth is expected to pick up the pace.</p><p>In the first quarter of fiscal 2023, which ended on Sept. 30, Microsoft clocked $50.1 billion in revenue, an increase of 11% over the year-ago period. The tech giant&#39;s revenue was up 16% year over year in constant currency terms. Analysts expect Microsoft to finish the fiscal year with 7% revenue growth, but fiscal 2024 is expected to be stronger with a 13% spike in revenue to $241 billion.</p><p>What&#39;s more, the company&#39;s momentum is anticipated to continue in fiscal 2025 as well.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c0a2ff6cb18a6fae2897305b7fc6ccd4\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>MSFT Revenue Estimates for Current Fiscal Year data by YCharts</span></p><p>It is impressive to see Microsoft thriving at a time when sales of personal computers are declining and the video gaming market is not in the best of health. Microsoft&#39;s reliance on cloud computing for a huge chunk of its revenue helped it offset the weakness in other markets.</p><p>More specifically, Microsoft&#39;s revenue from the intelligent cloud segment increased an impressive 20% year over year last quarter to $20.3 billion, accounting for 40% of the company&#39;s top line. Synergy Research Group estimates that Microsoft controlled 21% of the cloud infrastructure market in the third quarter of 2022. The market research firm also added that the cloud infrastructure service market in which Microsoft operates generated $217 billion in revenue in the trailing 12 months that ended in September.</p><p>Mordor Intelligence forecasts that the cloud infrastructure services market could clock annual growth of 19% through 2026, suggesting that Microsoft&#39;s biggest business is on track to become bigger in the long run. Meanwhile, a recovery in the video gaming market should help Microsoft&#39;s Xbox business turn around in the long run.</p><p>Microsoft&#39;s revenue from the Xbox content and services business was down 3% year over year last quarter. Newzoo predicts that the global gaming market is on track to contract 4% this year to $184.4 billion, which explains the weakness in Microsoft&#39;s gaming business. But by 2025, the global games market is expected to generate $211.2 billion in revenue.</p><p>This secular growth opportunity combined with Microsoft&#39;s steps to corner a bigger share of the video gaming market should give investors optimism about the health of the gaming business in the long run.</p><p>In all, Microsoft could see better days in 2023 and beyond thanks to the catalysts discussed above, which is why savvy investors should consider buying it given the attractive valuation.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Nasdaq Stock to Avoid Like the Plague in 2023, and 1 to Buy Hand Over Fist</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Nasdaq Stock to Avoid Like the Plague in 2023, and 1 to Buy Hand Over Fist\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-15 11:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/12/13/1-nasdaq-stock-to-avoid-2023-and-1-to-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>With 2022 about to come to an end, it is safe to say that this has been a year investors would like to forget. It has been a terrible one for the stock market, as evidenced by the steep 30% decline in...</p>\n\n<a href=\"https://www.fool.com/investing/2022/12/13/1-nasdaq-stock-to-avoid-2023-and-1-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4581":"高盛持仓","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","BK4512":"苹果概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0061474705.USD":"THREADNEEDLE (LUX) GLOBAL DYNAMIC REAL RETURN \"AU\" (USD) ACC","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","BK4548":"巴美列捷福持仓","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0276348264.USD":"THREADNEEDLE (LUX) GLOBAL DYNAMIC REAL RETURN\"AUP\" (USD) INC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","IE00BFSS8Q28.SGD":"Janus Henderson Balanced A Inc SGD-H","BK4528":"SaaS概念","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","BK4554":"元宇宙及AR概念","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","LU2286300806.USD":"Allianz Cyber Security AT Acc USD","BK4532":"文艺复兴科技持仓","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","BK4553":"喜马拉雅资本持仓","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","BK4567":"ESG概念","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4534":"瑞士信贷持仓","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","BK4576":"AR","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","MU":"美光科技","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","BK4575":"芯片概念","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","MSFT":"微软","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC","BK4535":"淡马锡持仓","LU0079474960.USD":"联博美国增长基金A","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","BK4141":"半导体产品","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","LU0061474960.USD":"天利环球焦点基金AU Acc","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0308772762.SGD":"Blackrock Global Allocation A2 SGD-H","BK4503":"景林资产持仓","LU0109392836.USD":"富兰克林科技股A","BK4097":"系统软件"},"source_url":"https://www.fool.com/investing/2022/12/13/1-nasdaq-stock-to-avoid-2023-and-1-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2291796194","content_text":"With 2022 about to come to an end, it is safe to say that this has been a year investors would like to forget. It has been a terrible one for the stock market, as evidenced by the steep 30% decline in the Nasdaq Composite index so far this year.The good news for investors is that there's potential for a bull market next year as slowing inflation could lead the Federal Reserve to ease the pace of interest rate hikes. That makes now a good time to consider a beaten-down Nasdaq stock with the potential to take off in 2023. At the same time, investors should steer clear of certain Nasdaq names that may continue to struggle even in a bull market.Micron Technology and Microsoft have borne the brunt of the Nasdaq's drop this year. Micron is down 41% in 2022 and shares of Microsoft have dropped 27%. One of these two Nasdaq stocks is likely to take off in the new year and the other one could continue to struggle.Let's see which one of these tech stocks investors should consider buying hand over fist and which one they should be avoiding like the plague.Micron Technology is going to enter the new year on the back footThe decline in the demand for memory chips this year really hit Micron stock. Gartner estimates that sales of dynamic random access memory (DRAM) chips that are used in personal computers (PCs), smartphones, workstations, and data centers could decline 2.6% in 2022 to $90.5 billion. That's not surprising as sales of both smartphones and PCs dropped this year.DRAM chips produced 72% of Micron's total revenue in the fourth quarter of fiscal 2022 (for the three months ending Sept. 1). This explains why lower DRAM shipments combined with a drop in average selling prices led to a 20% year-over-year decline in the chipmaker's quarterly revenue to $6.6 billion. The memory specialist's non-GAAP (adjusted) earnings fell to $1.45 per share from $2.42 per share in the prior-year period as the adjusted operating margin shrank to 25% from 37.1% in the prior year.The new year could be even worse for Micron. That's because Gartner sees DRAM industry revenue declining at a greater pace of 18% in 2023 to $74 billion. Meanwhile, the NAND flash memory business that produced 25% of Micron's revenue last quarter is also anticipated to turn negative next year. Gartner estimates a 13.7% decline in NAND flash industry revenue to $59 billion following a 4.4% increment in 2022.Not surprisingly, Micron's guidance for the first quarter of fiscal 2023 suggests it is about to have a terrible year. The chipmaker guided for $4.25 billion in revenue and $0.07 per share in earnings, which would translate into a huge decline over the prior-year period's revenue of $7.69 billion and adjusted earnings of $2.16 per share.Even worse, analysts forecast a 40% drop in Micron's top line in fiscal 2023. Its earnings are expected to shrink to just $0.25 per share from fiscal 2022's figure of $8.35 per share. These numbers suggest that Micron could head lower in the new year, which is why investors should steer clear of this struggling tech stock.Microsoft could step on the gasMicrosoft's woeful stock market performance in 2022 means that investors can buy this technology giant on the cheap right now. Microsoft stock is trading at 26 times earnings, a discount to its five-year average multiple of 37. Investors may not want to let such an opportunity slip by considering that Microsoft's growth is expected to pick up the pace.In the first quarter of fiscal 2023, which ended on Sept. 30, Microsoft clocked $50.1 billion in revenue, an increase of 11% over the year-ago period. The tech giant's revenue was up 16% year over year in constant currency terms. Analysts expect Microsoft to finish the fiscal year with 7% revenue growth, but fiscal 2024 is expected to be stronger with a 13% spike in revenue to $241 billion.What's more, the company's momentum is anticipated to continue in fiscal 2025 as well.MSFT Revenue Estimates for Current Fiscal Year data by YChartsIt is impressive to see Microsoft thriving at a time when sales of personal computers are declining and the video gaming market is not in the best of health. Microsoft's reliance on cloud computing for a huge chunk of its revenue helped it offset the weakness in other markets.More specifically, Microsoft's revenue from the intelligent cloud segment increased an impressive 20% year over year last quarter to $20.3 billion, accounting for 40% of the company's top line. Synergy Research Group estimates that Microsoft controlled 21% of the cloud infrastructure market in the third quarter of 2022. The market research firm also added that the cloud infrastructure service market in which Microsoft operates generated $217 billion in revenue in the trailing 12 months that ended in September.Mordor Intelligence forecasts that the cloud infrastructure services market could clock annual growth of 19% through 2026, suggesting that Microsoft's biggest business is on track to become bigger in the long run. Meanwhile, a recovery in the video gaming market should help Microsoft's Xbox business turn around in the long run.Microsoft's revenue from the Xbox content and services business was down 3% year over year last quarter. Newzoo predicts that the global gaming market is on track to contract 4% this year to $184.4 billion, which explains the weakness in Microsoft's gaming business. But by 2025, the global games market is expected to generate $211.2 billion in revenue.This secular growth opportunity combined with Microsoft's steps to corner a bigger share of the video gaming market should give investors optimism about the health of the gaming business in the long run.In all, Microsoft could see better days in 2023 and beyond thanks to the catalysts discussed above, which is why savvy investors should consider buying it given the attractive valuation.","news_type":1},"isVote":1,"tweetType":1,"viewCount":181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815834802,"gmtCreate":1630664153206,"gmtModify":1676530369992,"author":{"id":"3575010783330312","authorId":"3575010783330312","name":"咸蛋超人POT","avatar":"https://static.tigerbbs.com/ffe12d12ec49236cc05d807be8348dc0","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>It's almost time to average in at current price levels. &nbsp;Baby steps at a time, go easy. &nbsp;[YoYo]&nbsp;[Call]&nbsp;","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>It's almost time to average in at current price levels. &nbsp;Baby steps at a time, go easy. &nbsp;[YoYo]&nbsp;[Call]&nbsp;","text":"$Cassava Sciences Inc(SAVA)$It's almost time to average in at current price levels. Baby steps at a time, go easy. [YoYo] [Call]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815834802","isVote":1,"tweetType":1,"viewCount":272,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819437902,"gmtCreate":1630085057706,"gmtModify":1676530221747,"author":{"id":"3575010783330312","authorId":"3575010783330312","name":"咸蛋超人POT","avatar":"https://static.tigerbbs.com/ffe12d12ec49236cc05d807be8348dc0","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Lunch break isover, time to go GREEN![Smart]&nbsp;","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Lunch break isover, time to go GREEN![Smart]&nbsp;","text":"$Cassava Sciences Inc(SAVA)$Lunch break isover, time to go GREEN![Smart]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819437902","isVote":1,"tweetType":1,"viewCount":448,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9000976274,"gmtCreate":1639789385814,"gmtModify":1676533494531,"author":{"id":"3575010783330312","authorId":"3575010783330312","name":"咸蛋超人POT","avatar":"https://static.tigerbbs.com/ffe12d12ec49236cc05d807be8348dc0","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Time to trap the short sellers","listText":"Time to trap the short sellers","text":"Time to trap the short sellers","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000976274","repostId":"1108682296","repostType":2,"isVote":1,"tweetType":1,"viewCount":223,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}